Early prediction of the efficacy of 177Lu-DOTATATE in patients with metastatic neuroendocrine tumors

#3627

Introduction: PRRT has a major place in the therapeutic strategy of metastatic NETs. Its efficacy is generally evaluated after four cycles, with no early predictor identified to date. During each PRRT cycle, 177Lu-related gamma emissions can be measured by post-PRRT scintigraphy.

Aim(s): We explored whether the variation in tumor uptake on post-PRRT scintigraphy performed at C1 and C2 could predict the efficacy PRRT.

Materials and methods: We studied all consecutive patients who received at least 2 cycles of PRRT from 2013 to 2019 for metastatic NET. We calculated the C2/C1 ratio of liver metastases uptake (geometric mean of anterior and posterior uptakes) on post-PRRT scintigraphy. We explored the association between the C2/C1 ratio and the RECIST-defined response measured after C4, and progression free survival (PFS).

Conference:

Presenting Author:

Authors: Bando-Delaunay A, de Rycke O, Hentic O, Leclerc P, Allouch A,

Keywords: PRRT, scintigraphy, prediction, response,